Aligos reports positive data from Phase IIa MASH treatment trial [Yahoo! Finance]
Aligos Therapeutics, Inc. - Common stock (ALGS)
Company Research
Source: Yahoo! Finance
clinical trial of ALG-055009, a thyroid hormone receptor beta agonist, for treating metabolic-dysfunction-associated steatohepatitis (MASH). The double-blind, randomised, placebo-controlled study enrolled 102 subjects with presumed MASH and stage I-III liver fibrosis. Subjects were assigned to receive one of four doses of ALG-055009 or placebo once a day for 12 weeks. The primary endpoint focused on the relative variation in liver fat content at week 12. Safety, pharmacokinetics (PK) and other non-invasive biomarkers/tests were also assessed in the trial. According to the findings, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat, with up to 70% of subjects experiencing a =30% relative decrease from baseline. The treatment also had a favourable tolerability profile, with no serious adverse events or signs of clinical hyper/hypothyroidism reported. Most of the treatment-emergent adverse events in the trial were observe
Show less
Read more
Impact Snapshot
Event Time:
ALGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALGS alerts
High impacting Aligos Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ALGS
News
- Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its price target lowered by analysts at HC Wainwright from $75.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire
- Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025GlobeNewswire
ALGS
Earnings
- 3/10/25 - Miss
ALGS
Sec Filings
- 3/12/25 - Form SCHEDULE
- 3/10/25 - Form S-8
- 3/10/25 - Form 10-K
- ALGS's page on the SEC website